UC San Diego researchers found a biological pathway involving Ral and CTSA that depletes liver LDL receptors, helping explain how high-cholesterol diets impair cholesterol clearance. A previously safety-tested CTSA inhibitor could advance to Phase 2 trials, though it has not yet been shown to lower cholesterol in people.